Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Patel, Krish [1 ]
Teschemaker, Anna [2 ]
Tian, Hongping [3 ]
Pyrih, Nick [3 ]
Kolvenbag, Geert [2 ]
Patel, Shweta [2 ]
Wahlstrom, Svea K. [4 ]
Cui, Lianzhou [3 ]
机构：
[1] Swedish Canc Inst, Seattle, WA USA
[2] AstraZeneca, Gaithersburg, MD USA
[3] Cobbs Creek Hlth Care, Newtown Sq, PA USA
[4] AstraZeneca, Wilmington, DE USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-194523
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7745 / 7745
页数：1
相关论文
共 50 条
  • [21] Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Alrawashdh, Neda
    Alkhatib, Nimer
    McBride, Ali
    Persky, Daniel
    Abraham, Ivo
    BLOOD, 2018, 132
  • [22] Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
    Michael Wang
    Simon Rule
    Pier Luigi Zinzani
    Andre Goy
    Olivier Casasnovas
    Stephen D. Smith
    Gandhi Damaj
    Jeanette K. Doorduijn
    Thierry Lamy
    Franck Morschhauser
    Carlos Panizo
    Bijal Shah
    Andrew Davies
    Richard Eek
    Jehan Dupuis
    Eric Jacobsen
    Arnon P. Kater
    Steven Le Gouill
    Lucie Oberic
    Tadeusz Robak
    Preetesh Jain
    Melanie M. Frigault
    Raquel Izumi
    Dorothy Nguyen
    Priti Patel
    Ming Yin
    Monika Długosz-Danecka
    Leukemia, 2019, 33 : 2762 - 2766
  • [23] Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Olivier
    Smith, Stephen D.
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Le Gouill, Steven
    Oberic, Lucie
    Robak, Tadeusz
    Jain, Preetesh
    Frigault, Melanie M.
    Izumi, Raquel
    Dorothy Nguyen
    Patel, Priti
    Yin, Ming
    Dlugosz-Danecka, Monika
    LEUKEMIA, 2019, 33 (11) : 2762 - 2766
  • [24] Real-World Treatment of Patients With Relapsed/Refractory Myeloma
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (06): : 379 - 385
  • [25] Treatment Outcomes and Survival Patterns of Asian Patients With Relapsed/Refractory Mantle Cell Lymphoma
    Tan, Jing Yuan
    Qiu, Tian Yu
    Chiang, Jianbang
    Tan, Ya Hwee
    Yang, Valerie Shiwen
    Chang, Esther Wei Yin
    Poon, Eileen
    Somasundaram, Nagavalli
    Farid, Mohamad
    Tao, Miriam
    Lim, Soon Thye
    Chan, Jason Yongsheng
    JOURNAL OF HEMATOLOGY, 2021, 10 (04) : 187 - 195
  • [26] MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS IBRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Telford, C.
    Kabadi, S.
    Abhyankar, S.
    Song, J.
    Signorovitch, J.
    Zhao, J.
    Yao, Z.
    VALUE IN HEALTH, 2019, 22 : S62 - S62
  • [27] Treatment Patterns and Health/Economic Outcomes in Relapsed/Refractory Follicular Lymphoma: A Real-World Study
    van der Jagt, Richard
    Hamm, Caroline
    Fleury, Isabelle
    Lambert-Obry, Veronique
    Laliberte, Avril Gouault
    Castonguay, Alex
    Wagner, Dennis
    Toltl, Lisa
    Lachaine, Jean
    BLOOD, 2017, 130
  • [28] Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Sarkozy, Clementine
    Traverse-Glehen, Alexandra
    Bachy, Emmanuel
    Karlin, Lionel
    Ghesquieres, Herve
    Besson, Herve
    Hermans, Ruben
    Healy, Nollaig
    Garside, Jamie
    Diels, Joris
    MacDougall, Finlay
    Pick-Lauer, Corinna
    Salles, Gilles
    BLOOD, 2017, 130
  • [29] Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
    Nastoupil, Loretta J.
    Andersen, Clark R.
    Ayers, Amy
    Wang, Yucai
    Habermann, Thomas M.
    Chihara, Dai
    Kahl, Brad S.
    Link, Brian K.
    Koff, Jean L.
    Cohen, Jonathon B.
    Martin, Peter
    Lossos, Izidore S.
    Stanchina, Michele
    Haddadi, Sara
    Casulo, Carla
    Ayyappan, Sabarish
    Lin, Ruitao
    Li, Ziyi
    Larson, Melissa A.
    Maurer, Matthew J.
    Huynh, Lynn
    Gao, Chi
    Ramasubramanian, Ramya
    Duh, Mei Sheng
    Mutebi, Alex
    Wang, Tongsheng
    Jun, Monika
    Wang, Anthony
    Kamalakar, Rajesh
    Kalsekar, Anupama
    Cerhan, James R.
    Flowers, Christopher R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (04):
  • [30] Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Alrawashdh, Neda
    McBride, Ali
    Slack, Marion
    Abraham, Ivo
    BLOOD, 2020, 136
12345